Duska Therapeutics, Inc.

Company acquires P2 receptor-based technology for potential glaucoma treatment

Published in Lab Business Week, July 17th, 2005

Duska Therapeutics, Inc., (DSKT) announced that it has acquired the exclusive rights to novel P2 receptor (P2R)-based proprietary technology aimed at the development of a new therapeutic modality for the treatment of glaucoma.

Scientists in Europe, from whom the technology was licensed by Duska, have demonstrated in an animal glaucoma model in vivo that increased intraocular pressure leads to the release of adenosine 5'-triphosphate (ATP) into the extracellular space in the eye, upregulation of the P2X7 receptor (P2X7R), and its activation by ATP. The activation of the P2X7R is known to open cell membrane pores, through which large molecules can enter and damage the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2005-07-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry